About CLINUVEL

Preclinical Testing

Preclinical tests assess the toxicity of a drug and examine its potential effects on the human body. The tests are conducted in-vitro (within the glass- test tubes, Petri dishes etc) and in-vivo (within the living - animal testing). These tests are required by pharmaceutical regulators to ensure that a drug is safe for human use prior to beginning human clinical trials.

Lab1
Preclinical testing in the lab

In-vivo trials may involve Pharmacokinetic (PK) and Pharmacodynamic (PD) studies, to begin to ascertain the drug's mechanism of action. PK and PD trials study what a body does to the drug and what a drug does to a body, respectively.  

Also investigated through pre-clinical trials is a drugs No Observable Effect Level (NOEL). This forms the starting point for subsequent trials and is the level at which the drug is dosed in amounts too small to have any measurable effect.

Latest Company Announcements

09 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More
10 May 2017

Appendix 3B

Appendix 3B

Read More
10 May 2017

CLINUVEL Newsletter - May 2017

I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end.

Read More
02 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

CLINUVEL announce that the Department of Health has designated SCENESSE® to be evaluated as a Highly Specialised Technology (HST)

Read More

Quick Links